Guardant Health Inc (Guardant Health) is a precision oncology company that commercializes novel therapeutics for cancer. The company develops proprietary digital sequencing technology used to detect individual genomic alterations. It offers Guardant360, a tool for early cancer detection used during cancer treatment for residual disease monitoring and also recurrence monitoring. The company test platform includes GuardantOMNI, GuardantINFINITY and GuardantINFORM. Guardant Health also develops a cloud-based information platform for liquid biopsy-based genomic testing in cancer treatments. The company provides somatic alterations across all solid tumor sites. Guardant Health is headquartered in Pao Alto, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Guardant Health Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Guardant Health Inc Company Overview
- Guardant Health Inc Company Snapshot
- Guardant Health Inc Pipeline Products and Ongoing Clinical Trials Overview
- Guardant Health Inc - Pipeline Analysis Overview
- Guardant Health Inc - Key Facts
- Guardant Health Inc - Major Products and Services
- Guardant Health Inc Pipeline Products by Development Stage
- Guardant Health Inc Ongoing Clinical Trials by Trial Status
- Guardant Health Inc Pipeline Products Overview
- Anti-RSP03 Antibody Based Blood Test
- Anti-RSP03 Antibody Based Blood Test Product Overview
- cfDNA Diagnostic Assay
- cfDNA Diagnostic Assay Product Overview
- Gene-Based Test - Lung Cancer
- Gene-Based Test - Lung Cancer Product Overview
- Gene-Based Test - Lung Cancer Clinical Trial
- Guardant Reveal Blood Test - Multiple Cancers
- Guardant Reveal Blood Test - Multiple Cancers Product Overview
- Guardant Reveal Blood Test - Multiple Cancers Clinical Trial
- Guardant Shield IVD-CRC Test
- Guardant Shield IVD-CRC Test Product Overview
- Guardant Shield IVD-CRC Test Clinical Trial
- Guardant360 CDx
- Guardant360 CDx Product Overview
- Guardant360 CDx Clinical Trial
- Guardant360 CDx Test - Amivantamab
- Guardant360 CDx Test - Amivantamab Product Overview
- Guardant360 CDx Test - Camizestrant
- Guardant360 CDx Test - Camizestrant Product Overview
- Guardant360 CDx Test - Lumakras
- Guardant360 CDx Test - Lumakras Product Overview
- Guardant360 CDx Test - Lumakras Clinical Trial
- Guardant360 CDx Test - Pembrolizumab
- Guardant360 CDx Test - Pembrolizumab Product Overview
- Guardant360 CDx Test - Taletrectinib
- Guardant360 CDx Test - Taletrectinib Product Overview
- Guardant360 CDx Test - Tepotinib
- Guardant360 CDx Test - Tepotinib Product Overview
- Guardant360 Companion Diagnostic Assay - Glesatinib
- Guardant360 Companion Diagnostic Assay - Glesatinib Product Overview
- Guardant360 Liquid Biopsy Test
- Guardant360 Liquid Biopsy Test Product Overview
- Guardant360 TissueNext - Taletrectinib
- Guardant360 TissueNext - Taletrectinib Product Overview
- Guardant360 TissueNext PD-L1 Test
- Product Status
- GuardantOMNI Test - Imfinzi
- GuardantOMNI Test - Imfinzi Product Overview
- LUNAR-2 Assay
- LUNAR-2 Assay Product Overview
- LUNAR-2 Assay Clinical Trial
- Next Generation Guardant Shield Blood Test
- Next Generation Guardant Shield Blood Test Product Overview
- Next Generation Guardant Shield Blood Test Clinical Trial
- Next-Generation CGP Tissue Assay
- Next-Generation CGP Tissue Assay Product Overview
- Smart Liquid Biopsy
- Smart Liquid Biopsy Product Overview
- Guardant Health Inc - Key Competitors
- Guardant Health Inc - Key Employees
- Guardant Health Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Guardant Health Inc, Recent Developments
- May 31, 2023: Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting
- Apr 11, 2023: Guardant Health to present data from 14 studies highlighting advances in precision oncology and cancer screening at 2023 AACR Annual Meeting
- Feb 27, 2023: Musa Tariq Joins Guardant Health Board of Directors
- Feb 02, 2023: Magistrate Judge issues favorable recommendation regarding Guardant Health’s Motion to dismiss lawsuit brought by Illumina
- Feb 01, 2023: Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
- Feb 01, 2023: Sampled’s Genomics Laboratory in Glasgow launches inaugural project with Guardant Health
- Jan 09, 2023: Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results
- Nov 03, 2022: Guardant Health Reports Third Quarter 2022 Financial Results
- Sep 09, 2022: Guardant Health introduces GuardantINFINITY smart liquid biopsy for research use to help bring new cancer therapies to patients sooner
- Aug 09, 2022: Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM™ Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Guardant Health Inc Pipeline Products and Ongoing Clinical Trials Overview
- Guardant Health Inc Pipeline Products by Equipment Type
- Guardant Health Inc Pipeline Products by Indication
- Guardant Health Inc Ongoing Clinical Trials by Trial Status
- Guardant Health Inc, Key Facts
- Guardant Health Inc, Major Products and Services
- Guardant Health Inc Number of Pipeline Products by Development Stage
- Guardant Health Inc Pipeline Products Summary by Development Stage
- Guardant Health Inc Ongoing Clinical Trials by Trial Status
- Guardant Health Inc Ongoing Clinical Trials Summary
- Anti-RSP03 Antibody Based Blood Test - Product Status
- Anti-RSP03 Antibody Based Blood Test - Product Description
- cfDNA Diagnostic Assay - Product Status
- cfDNA Diagnostic Assay - Product Description
- Gene-Based Test - Lung Cancer - Product Status
- Gene-Based Test - Lung Cancer - Product Description
- Gene-Based Test - Lung Cancer - Prospective Feasibility Study of Cell Free Circulating Tumor DNA for the Diagnosis and Treatment Monitoring in Early-stage Non-small Cell Lung Cancer
- Guardant Reveal Blood Test - Multiple Cancers - Product Status
- Guardant Reveal Blood Test - Multiple Cancers - Product Description
- Guardant Reveal Blood Test - Multiple Cancers - ORACLE: Observation of ResiduAl Cancer with Liquid Biopsy Evaluation
- Guardant Shield IVD-CRC Test - Product Status
- Guardant Shield IVD-CRC Test - Product Description
- Guardant Shield IVD-CRC Test - The Ohio State University Guardant Shield Colorectal Cancer Screening Project
- Guardant Shield IVD-CRC Test - Understanding Patient Preference on Colorectal Cancer Screening Options
- Guardant360 CDx - Product Status
- Guardant360 CDx - Product Description
- Guardant360 CDx - A Multiple Parallel Cohort, Multi-centre Phase IIa Trial Aiming to Provide Proof of Principle Efficacy for Designated Targeted Therapies in Patients with Advanced Breast Cancer Where the Targetable Mutation is Identified Through ctDNA
- Guardant360 CDx - A Prospective Observational Study on the Efficacy of Multiplex Genetic Analysis by Means of a Next-generation Sequencer Using Cell-free DNA
- Guardant360 CDx - An Ambitious Multi-arm, Multi-site Umbrella Trial to Study Blood Test for Early Cancer Detection
- Guardant360 CDx - An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Guardant360 CDx - Multicenter Phase II Study to Evaluate Efficacy and Safety of Combination Therapy with Trastuzumab and Pertuzumab in Patients with HER2-positive Metastatic Colorectal Cancer
- Guardant360 CDx - Open-label, Phase II Study of Trastuzumab in Combination with Lapatinib (Cohort A) or Pertuzumab in Combination with Trastuzumab-emtansine (Cohort B) in Patients with HER2-positive Metastatic Colorectal Cancer: The HERACLES (HER2 Amplification for Colo-rectal Cancer Enhanced Stratification)Trial
- Guardant360 CDx - Research on Liquid Biopsy in Patients with Gastrointestinal and Abdominal Malignancies, Including Colorectal Cancer
- Guardant360 CDx Test - Amivantamab - Product Status
- Guardant360 CDx Test - Amivantamab - Product Description
- Guardant360 CDx Test - Camizestrant - Product Status
- Guardant360 CDx Test - Camizestrant - Product Description
- Guardant360 CDx Test - Lumakras - Product Status
- Guardant360 CDx Test - Lumakras - Product Description
- Guardant360 CDx Test - Lumakras - A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects with Advanced NSCLC with KRAS p.G12C Mutation: CodeBreak 100
- Guardant360 CDx Test - Pembrolizum
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- NantHealth Inc
- ElSohly Laboratories Inc
- Illumina Inc
- BioGenex Laboratories Inc
- InVitae Corp
- Qiagen NV
- Natera Inc
- Thermo Fisher Scientific Inc
- Novartis Pharmaceuticals Corp
- Roche Molecular Systems Inc
- Natera Inc
- Roche Molecular Systems Inc
- InVitae Corp
- NantHealth Inc
- Qiagen NV
- Thermo Fisher Scientific Inc
- BioGenex Laboratories Inc
- Novartis Pharmaceuticals Corp
- ElSohly Laboratories Inc
- Illumina Inc
